key: cord-0287572-cfvz0dyz
authors: Hutchinson, N.; Klas, K.; Carlisle, B. G.; Kimmelman, J.; Waligora, M.
title: How Informative were Early SARS-CoV-2 Treatment and Prevention Trials? A longitudinal cohort analysis of trials registered on clinicaltrials.gov
date: 2021-09-05
journal: nan
DOI: 10.1101/2021.08.25.21262155
sha: af1771009226872b68ffd7153410aa4c922a5205
doc_id: 287572
cord_uid: cfvz0dyz

Background Early in the SARS-CoV-2 pandemic, commentators warned that some COVID trials were inadequately conceived, designed and reported. Here, we retrospectively assess the prevalence of informative COVID trials launched in the first 6 months of the pandemic. Methods We created a cohort of SARS-CoV-2 treatment and prevention efficacy trials that were initiated from 2020-01-01 to 2020-06-30 using ClinicalTrials.gov registration records. We evaluated trials on 3 criteria of informativeness: potential redundancy, design quality and feasibility of patient-participant recruitment. The study protocol was prospectively registered with the Open Science Framework (https://osf.io/fp726/). Results We included 500 trials in our cohort, 58% of which were Phase 2 and 84.8% were directed towards the treatment of SARS-CoV-2. Close to one third of trials met all three criteria and were deemed informative (29.0% (95% Confidence Interval 23.7-36.9)). The proportion of potentially redundant trials in our cohort was 4.1%. Over half of the trials in our cohort (56.2%) did not meet our criteria for high quality trial design. The proportion of trials with infeasible patient-participant recruitment was 22.6%. Conclusions Less than one third of COVID-19 trials registered on ClinicalTrials.gov during the first six months met all three criteria for informativeness. Shortcomings in trial design, recruitment feasibility and redundancy reflect longstanding weaknesses in the clinical research enterprise that were likely amplified by the exceptional circumstances of a pandemic.

Starting in early 2020, commentators warned of COVID-19 clinical trial design deficiencies and lack of coordination of research efforts. [1] [2] [3] [4] The large volume of small trials investigating the efficacy of repurposed medications, such as hydroxychloroquine, in the treatment of COVID-19, drew particular attention. 5, 6 Such studies confounded an effective public health response by producing spurious findings, or by diverting patients and resources from well designed and executed studies.

Appropriate design, implementation and reporting is captured by the concept of trial "informativeness". 3, 7 For a trial to be informative, it must ask a clinically important question, be designed to provide a clear answer, be feasible, be analyzed in a manner that supports statistically valid inference, and report results in a complete and timely manner. 3, 7 In the following longitudinal cohort analysis of SARS-CoV-2 treatment and prevention trials registered within the first 6 months of 2020, we assess three features of an informative clinical trial -potential redundancy, design quality and feasibility of patientparticipant recruitment. Multiple cross-sectional analyses and systematic reviews of SARS-CoV-2 treatment and prevention trials have been performed, 2,5,6,8-10 reporting on intervention types, study characteristics and choice of outcome measure. We go beyond a description of trial characteristics and provide the first in-depth evaluation of SARS-CoV-2 trial informativeness. Knowing the prevalence of potentially uninformative trials . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08. 25.21262155 doi: medRxiv preprint conducted in the early stages of the pandemic can help motivate the development of more effective research policy in anticipation of future public health crises.

Our cohort consisted of interventional SARS-CoV-2 treatment and prevention trials registered on ClinicalTrials.gov with a start date between 2020-01-01 and 2020-06-30.

We included Phase 1/2, Phase 2, Phase 2/3 and Phase 3 trials testing an efficacy hypothesis in their primary outcome. We included trials evaluating any of the following interventions: drug, biological, surgical, radiotherapy, procedural or device (see S1 File for complete inclusion/exclusion criteria). Trial inclusion was independently assessed by two researchers (KK & LZ). We did not perform a sample size calculation, as we included all trials meeting our eligibility criteria within our designated sampling timeframe.

We downloaded clinical trial data directly as a zipped folder of XML files from the web front-end of ClinicalTrials.gov on 2020-12-01 and again on 2021-01-04. This allowed us to evaluate data at the 6-month mark (from date of trial start) for all trials in our cohort (see S2 File for data directly downloaded from ClinicalTrials.gov). Additional items . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.25.21262155 doi: medRxiv preprint requiring human curation were independently assessed and coded by two researchers (KK & LZ), these included: i) treatment type (according to the World Health Organization (WHO) COVID-19 Classification of treatment types 11 ); ii) illness severity (as stated by the study investigators or guided by the WHO disease severity classification 12 ); iii) location of care (ambulatory, hospitalized, intensive care, unclear/not stated); iv) presence of a placebo or standard of care arm; and, v) type of primary outcome (clinical, surrogate, procedural) (see S3 File for additional double-coded data points).

Trials were assessed based on three elements of informativeness articulated elsewhere: 3,7 i) potential redundancy (as a marker of trial importance); ii) trial design quality; and iii) successful patient-participant recruitment (as a marker of feasibility).

Assessment criteria for each element were designed based on face validity and easy applicability over a large trial sample.

We assessed potential redundancy by evaluating non-redundancy of the trial hypothesis. Non-redundancy was defined as: absence of a trial of the same phase, type of trial (SARS-CoV-2 prevention versus treatment), patient-participant characteristics (including location of care, disease severity and age of trial participants), regimen (including interventions used in combination in a single arm), comparator arm(s) and primary outcome (evaluating primary outcome domain and specific measurement, . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.25.21262155 doi: medRxiv preprint based on framework from 13 ) launched prior to the start date of the trial of interest (as indicated in the registration record active at the 6-month mark since trial start) (S4 File).

Only the trial with the later start date was labelled as potentially redundant. The assessment was independently performed by two raters (NH & KK). We performed an additional post hoc assessment applying a broad criterion for trial similarity, which we defined as presence of a trial with an earlier start date of the same type, phase, patientparticipant characteristics and treatment regimen.

We analyzed trial design quality for those studies in our sample that were aimed at informing clinical practice -namely Phase 2/3 and Phase 3 trials. Based on the U.S.

Food & Drug Association (FDA) May 2020 guidance document for SARS-CoV-2 drug and biological treatment and prevention trials, 14 we considered a trial to be welldesigned if it was randomized, placebo-controlled (with appropriate standard of care in all arms), double-blinded and included participants aged 60 years or over (as a proxy for an at-risk population). To be considered well-designed, a trial must also measure an appropriate primary outcome -a clinical primary outcome in the case of trials aimed at treating COVID-19, or the presence of laboratory-confirmed SARS-CoV-2 infection for trials testing a preventive measure.

We assessed timeliness and success of patient-participant recruitment for each trial in our cohort. A single trial was considered non-feasible if it met any of the following . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.25.21262155 doi: medRxiv preprint criteria: i) trial status was "terminated" or "suspended" and reason for stopping contained a rationale unrelated to trial efficacy, safety or the progression of science; ii) trial status was "completed" or "active, not recruiting" and final enrollment was less than 85% of the anticipated enrollment reported in the trial registration at the time of trial launch (given concerns for compromised statistical power for the primary outcome when recruitment is below the stated threshold (based on previously published methods 15 ); or, iii) trial status was "recruiting" or "enrolling by invitation" and the recruitment period had been extended to at least twice as long as the anticipated length in the version of ClinicalTrials.gov registration record at the time of trial start.

We report the overall proportion of trials meeting all three criteria of informativeness (potential redundancy, design quality and feasibility of patient-participant recruitment) as well as the proportion meeting each of our three criteria. We performed a stratified analysis of the proportion of i) non-redundant; ii) well-designed; and iii) feasible trials by sponsor (industry versus non-industry), trial country location (USA versus non-USA), trial type (treatment versus prevention) and number of trial centers (single center versus multicenter). Ninety-five percent confidence intervals were calculated for each proportion and the Fisher's exact test was used to compare proportions within each group and calculate p-values. We defined p < 0.05 as statistically significant. All tests were 2-tailed.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.25.21262155 doi: medRxiv preprint

We performed data extraction using Numbat Systematic Review Manager v. 2.11 (RRID:SCR_019207). 16 All analyses were performed using R version 3.6.3. 17 We retrieved historical versions of ClinicalTrials.gov using Clinical Trials History Scraper (RRID:SCR_019229).

Our study was not subject to Institutional Review Board approval, as it relies on publicly accessible data and did not involve interaction with research participants. The study protocol was prospectively registered on Open Science Framework. 18 We listed the deviations from the protocol in S5 File. The code 19 and data sets 18 used in this analysis are available online.

We included 500 interventional SARS-CoV-2 treatment and prevention efficacy trials (see S1 Figure for PRISMA Diagram). The majority (58.0%) of trials in our cohort were Phase 2 trials; 84.6% were randomized; 84.8% were directed at the treatment of SARS-CoV-2. Study status at 6 months since trial start was "completed" in 54 of 500 trials (10.8%) and "Recruiting" in 67.0% (Table 1) . Median anticipated enrollment per trial (based on the enrollment stated in the last registration record prior to trial start) was 180 patient-participants (interquartile range (IQR) 60-437). Median actual patient-participant . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.25.21262155 doi: medRxiv preprint enrollment at the 6-month mark, for those trials that provided actual enrollment numbers, was 129 (IQR 32-320).

Less than one third (29.9%, 95% CI 23.7-36.9%) of the 194 trials eligible for assessment of all 3 criteria were deemed informative. Nineteen trials were classified as potentially redundant (4.1%), of which 10 investigated convalescent plasma and a further 4 investigated hydroxychloroquine. Sixty-three trials (13.6%) differed only by primary outcome. In our post hoc analysis, 81.9% (380 of 464 trials) were similar with respect to trial type, regimen, phase and patient-participant characteristics.

Of the subset of 210 Phase 2/3 and Phase 3 trials in our cohort, 92 (43.8%) met our criteria for trial design quality 20 ( Figure 1 ; Table 2 ). The proportion of feasible trials in our cohort was 77.4% (387 of 500 trials); 113 trials were non-feasible. Of these, 12 were suspended or terminated for a reason unrelated to efficacy, safety or the progression of science; 20 trials were "active, not recruiting" or completed but failed to enrol at least 85% of their target patient-participant enrollment (S2 Figure) ; 81 trials still recruiting had exceeded at least two times the intended recruitment period (S3 Figure) .

This is the first study to assess the prevalence of informative COVID-19 clinical trials. In our analysis, 29.9% of early COVID-19 trials registered on ClinicalTrials.gov met our 3 criteria for informativeness. Many (56.2%) did not use rigorous design, based on . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 5, 2021. ;  assessment of randomization, control group, blinding, primary outcome, and inclusion of an at-risk population. Of these, the greatest number (110 of 210 trials, 52.4%) did not demonstrate adequate blinding. Lack of blinding among COVID-19 trials has been highlighted in several recent analyses 2,5,6,9,10 and may reflect the challenges of trial conduct in pandemic circumstances, in which significant research infrastructure and oversight is required to implement and maintain blinding. Yet, deficits in trial design were not uniform. Our stratified results (Table 3) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.25.21262155 doi: medRxiv preprint counts, have also been documented during the COVID-19 pandemic. 24 Trial feasibility may be particularly challenging in the fractured US healthcare setting due to inter-trial competition in patient-participant recruitment, as supported by our stratified analysis in which non-USA trials were significantly more likely to be feasible than USA trials. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.25.21262155 doi: medRxiv preprint through meta-analyses. This is particularly relevant in the setting of multiple small trials of specific interventions, where the probability is elevated that at least one trial produces a positive result by chance alone. 2, 5 Concerns regarding research waste predated the pandemic 27-33 but intensified in the setting of this international public health crisis. Our results support arguments for devising coordinated research plans in advance of public health emergencies, and evaluating and prioritizing trials at institutional, 34,35 state and national levels. 36 The success of multicenter national platform trials, such as RECOVERY, in the United Kingdom, in both recruiting patient-participants (over 41000 have been enrolled as of August 9 2021, https://www.recoverytrial.net) and in generating practice-changing evidence, speaks to the promise of national research prioritization. 37 In our stratified analysis, industry-sponsored trials were significantly more likely to meet all 3 informativeness criteria than non-industry sponsored trials (Table 3 ). This suggests that academic researchers require more institutional support, as well as assistance from research consortia and funding bodies to produce informative results.

First, we limited our assessment to 3 aspects of trial informativeness -potential redundancy, design quality and feasibility of patient-participant recruitment. Other aspects of informativeness, such as integrity and reporting, were not evaluated in our study, as they cannot be assessed without access to final trial results (430 of 500 trials, . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.25.21262155 doi: medRxiv preprint 86.0% had not yet completed or terminated at the end of our 6-month follow-up period).

Second, we used proxy measures of informativeness, which are imperfect. For example, we adopted strict criteria for potential redundancy, resulting in only 19 trials labelled potentially redundant, many of which differed based on primary outcome alone.

Our post hoc analysis resulted in over eighty percent of trials deemed similar, based on assessment of trial type, regimen, phase and patient-participant characteristics. These two results (4.1% and 81.9%) can be viewed as lower and upper bounds for the proportion of redundant trials. Future research will be required to provide a more precise estimate post-pandemic. Our assessment of trial design quality, as guided by the May 2020 FDA guidance document, 14 required that all trials be, at a minimum, doubleblinded. We acknowledge that this may unfairly penalize the small minority of trials evaluating interventions in which double-blinding is not practicable. In addition, our assessment of the inclusion of at-risk populations was limited only to age. We did not assess whether the study included a population with other risk factors such as comorbidities. However, no trials failed our design criteria based on failure to include an at-risk population. Third, our assessment of the informativeness of COVID-19 trials depends on the accuracy of ClinicalTrials.gov registration records.

The SARS-CoV-2 pandemic was met with a vigorous response from clinical researchers. However, less than one third of early COVID-19 trials registered on ClinicalTrials.gov met our 3 criteria for informativeness. Shortcomings in trial design, . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.25.21262155 doi: medRxiv preprint recruitment feasibility and redundancy reflect longstanding vulnerabilities in the clinical research enterprise that were magnified by the urgency of a pandemic. Much knowledge has been gained during the past 18 months, both in terms of effective measures aimed at treatment and prevention of the virus, but also with respect to the conduct of informative clinical research. The task ahead will be for investigators, research institutions, sponsors and regulators alike to take stock of lessons learned and devise solutions to benefit the global research enterprise as we move forward. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.25.21262155 doi: medRxiv preprint funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The datasets generated and analysed during the current study are available in the Open Science Framework repository, https://osf.io/fp726/.

Not applicable.

Marcin Waligora reports personal fees from Advisory Bioethics Council, Sanofi outside the submitted work. Other authors have declared that no competing interests exist.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 5, 2021. a) Anticipated enrollment in the first registration record after trial start b) At the 6-month mark, for the subset of trials which provide actual enrollment information c) Includes Phase 1/2 d) Includes Phase 2/3 e) NA -Information not available in the ClinicalTrials.gov registration record f) Trial Status at the 6-month mark since trial start . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.25.21262155 doi: medRxiv preprint a) Refers to trials that were at a minimum double-blinded b) Treatment trials required a primary clinical outcome; prevention trials required either a primary clinical outcome or laboratory-confirmed SARS-CoV-2 c) Age of participants ³ 60; the two trials not including participants ³ 60 years of age included healthy adults without any additional factors putting them at greater risk for severe SARS-CoV-2 disease . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.25.21262155 doi: medRxiv preprint a) Informative trials are those that meet all 3 informativeness criteria . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.08.25.21262155 doi: medRxiv preprint

Waste in covid-19 research

Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic

Against pandemic research exceptionalism

Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19

Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis

Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis

Harms From Uninformative Clinical Trials

Review of trials currently testing treatment and prevention of COVID-19

Characteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov

The worldwide clinical trial research response to the COVID-19 pandemic -the first 100 days

World Health Organization. WHO R&D Blueprint COVID 19 Experimental Treatments

Clinical management of COVID-19 Interim Guidance

The ClinicalTrials.gov results database--update and key issues

Food & Drug Association. COVID 19: Developing Drugs and Biological Products for Treatment or Prevention, Guidance for Industry

Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials

Numbat Systematic Review Manager. The Grey Literature

R: A language and environment for statistical computing. R Foundation for Statistical Computing

The informativeness of trials in COVID-19: Lessons learned from the Coronavirus pandemic

Recruitment and Results Reporting of COVID-19 Randomized Clinical Trials Registered in the First 100 Days of the Pandemic

Remdesivir for COVID-19: challenges of underpowered studies. The Lancet

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet

Vaccines against Ebola virus. Vaccine

How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis

Harmonizing Heterogeneous Endpoints in Coronavirus Disease 2019 Trials Without Loss of Information

Lack of harmonization of coronavirus disease ordinal scales

How to increase value and reduce waste when research priorities are set. The Lancet

Increasing value and reducing waste: addressing inaccessible research. The Lancet

Reducing waste from incomplete or unusable reports of biomedical research

Increasing value and reducing waste in research design, conduct, and analysis. The Lancet

Increasing value and reducing waste in biomedical research: who's listening? The Lancet

Increasing value and reducing waste in biomedical research regulation and management. The Lancet

Avoidable waste of research related to outcome planning and reporting in clinical trials

When clinical trials compete: prioritising study recruitment

Improving Clinical Trial Enrollment -In the Covid-19 Era and Beyond

An ethics framework for consolidating and prioritizing COVID-19 clinical trials

Emerging Lessons from COVID-19 for the US Clinical Research Enterprise